Epstein Secrets

t on Monday, Speaker Nancy Pelosi informed colleagues that she intended to schedule a full House vote "soon" to hold Mr. Barr and Commerce Secretary Wilbur Ross in contempt of Congress for defying subpoenas for documents related to the census question. Ms. Pelosi called the census dispute "essential to who

ith a contempt vote on the floor — and no date for a vote has yet been set — it would be empowering the Oversight Committee to take Mr. Barr and Mr. Ross to court to ask a judge to enforce their subpoenas. Doing so is an exceedingly rare step and puts a black mark on both officials' public records. T

t it contemplates his criminal prosecution." Kordel, 397 U.S. at 11-12 (emphasis added). In Kordel, a corporate executive was convicted of violating the Food, Drug, and Cosmetic Act partly on the basis of earlier answers to interrogatories served on his company by the Food and Drug Administration (FDA) in a ci

t on Monday, Speaker Nancy Pelosi informed colleagues that she intended to schedule a full House vote "soon" to hold Mr. Barr and Commerce Secretary Wilbur Ross in contempt of Congress for defying subpoenas for documents related to the census question. Ms. Pelosi called the census dispute "essential to who

ith a contempt vote on the floor — and no date for a vote has yet been set — it would be empowering the Oversight Committee to take Mr. Barr and Mr. Ross to court to ask a judge to enforce their subpoenas. Doing so is an exceedingly rare step and puts a black mark on both officials' public records. T

it contemplates his criminal prosecution." Kordel, 397 U.S. at 11-12 (emphasis added). In Kordel, a corporate executive was convicted of violating the Food, Drug, and Cosmetic Act partly on the basis of earlier answers to interrogatories served on his company by the Food and Drug Administration (FDA) in a ci

ct Court for the Dis- trict of South Carolina, G. Ross Anderson, Jr., J., certified class, and lender a

ith their access to the drug. The Supreme Court rejected the patients' claims. The Court agreed with FDA that the new drug approval provisions of the Food, Drug, and Cosmetic Act spe- cifically applied to the situation presented. (171 In one respect, however, the fact that Dr. Burzynski and his patients wer